Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients

• Published in: International journal of cancer Vol. 60; no. 6; p. 802
• Main Authors: Tani, M, Tanimura, H, Yamaue, H, Mizobata, S, Iwahashi, M, Tsunoda, T, Noguchi, K, Tamai, M, Hotta, T, Terasawa, H
• Format: Journal Article
• Language: English
• Published: United States 16-03-1995
• Subjects: Antibodies, Monoclonal - pharmacology; CD3 Complex - immunology; CD4-Positive T-Lymphocytes - cytology; CD4-Positive T-Lymphocytes - drug effects; CD4-Positive T-Lymphocytes - immunology; Cell Division; Cytotoxicity, Immunologic; Humans; Immunophenotyping; Interleukin-2 - pharmacology; Lymphocyte Activation; Major Histocompatibility Complex - immunology; Neoplasms - immunology
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910600613

The proliferation of autologous tumor-reactive cytotoxic T lymphocytes (CTL), induced by autologous mixed lymphocyte tumor-cell culture, was remarkably enhanced by activation with immobilized anti-CD3 monoclonal antibody (MAb) and interleukin-2 (IL-2), as compared with IL-2 alone. The activated CTL exhibited high cytotoxicity against autologous tumor cells. Cytotoxicity against autologous tumor cells was inhibited by anti-HLA-DR MAb. In negative selection with immunomagnetic beads, cytotoxicity against autologous tumor cells was inhibited by the elimination of CD4+ cells. The major cell-surface antigens of the activated CTL were CD3+, CD4+, CD25+, CD45RO+ and CD45RA-, suggesting helper T cells, and the activated CTL produced IL-2. It is concluded that the CTL activated by immobilized anti-CD3 MAb and IL-2 were CD4 cells that had both killer and helper functions. Our findings indicate that adoptive immunotherapy using these activated CTL would be effective in cancer patients.